Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TPIP F2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TPIP Dose A | EXPERIMENTAL | Participants will receive single dose of TPIP F2 or F3 on Day 1 in treatment period 1 followed by single dose of TPIP F3 or F2 on Day 1 in treatment period 2. Both treatment periods are separated by 7-day washout period. |
| TPIP Dose B | EXPERIMENTAL | Participants will receive single dose of TPIP F2 or F3 on Day 1 in treatment period 1 followed by single dose of TPIP F3 or F2 on Day 1 in treatment period 2. Both treatment periods are separated by 7-day washout period. |
| TPIP Dose C | EXPERIMENTAL | Participants will receive single dose of TPIP F2 or F3 on Day 1 in treatment period 1 followed by single dose of TPIP F3 or F2 on Day 1 in treatment period 2. Both treatment periods are separated by 7-day washout period. |
| Name | Type | Description |
|---|---|---|
| TPIP F2 | DRUG | Inhalation using a capsule-based dry powder inhaler device. |
| TPIP F3 | DRUG | Inhalation using a capsule-based dry powder inhaler device. |
Inclusion Criteria * Body mass index (BMI): 18.0 to 32.0 kilogram per square metre (kg/m\^2), inclusive, at screening. * Weight: ≥50 kg (kilograms), inclusive, at screening. * Must be a nonsmoker (no use of tobacco or nicotine products) and/or has not used chewing tobacco for at least 1 month prior...
TPIP F2 is an investigational small molecule being studied in healthy volunteers. It is a formulation of treprostinil palmitil inhalation powder, specifically Formulation 2, and is being evaluated for its relative bioavailability compared to another formulation. It is not approved for any disease and is in early clinical development.
TPIP F2 is being developed by Insmed Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker INSM. The company is conducting clinical research on this investigational drug candidate.
TPIP F2 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug remains in early-stage clinical research.
TPIP F2 has one completed Phase 1 clinical trial, identified as NCT07102316. The study assessed the relative bioavailability after a single inhalation administration of TPIP Formulation 2 compared to Formulation 3 in healthy participants. The trial enrolled 42 participants in the United States.
TPIP F2 is a specific formulation of treprostinil palmitil inhalation powder, referred to as Formulation 2. It is being compared to Formulation 3 in clinical trials. Treprostinil palmitil is the active moiety, and TPIP F2 is one of its formulations under investigation.